吉西他滨同药维持化疗治疗晚期肺鳞癌的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (30 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Gemcitabine with maintenance chemotherapy in the treatment of advanced lung squamous cell carcinoma. Methods A total of 68 patients with advanced lung squamous cell carcinoma admitted to Anshan Cancer Hospital from July 2016 to January 2020 were selected as the research objects. They were divided into the control group and the experimental group according to the random number table method, with 34 cases in each group. In the control group, best supportive treatment was used, and in the experimental group, Gemcitabine with maintenance chemotherapy was adopted. The clinical effect, incidence of adverse reactions and progression-free survival were compared between the two groups. Results There were no statistically significant differences in the total effective rate and disease control rate between the two groups (P＞0.05). The incidence rates of liver function damage, gastrointestinal reaction, hair loss and neurotoxicity in observation group were lower than those in control group, and the differences were statistically significant (P＜0.05). There were no statistically significant differences in the incidence rates of renal function impairment and rash between the two groups (P＞0.05). The progression-free survival in the experimental group was longer than that in the control group, and the difference was statistically significant (P＜0.05). Conclusion The clinical effect of maintenance chemotherapy with Gemcitabine for patients with advanced lung squamous cell carcinoma is the same as the best supportive treatment, but the incidence of adverse reactions is low and the progression-free survival period is high. It is worthy of promotion and application in future clinical practice.

Key words： Gemcitabine Chemotherapy Advanced lung squamous cell carcinoma Clinical effect Safety

Received: 21 September 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	BI Da-peng

Cite this article:

BI Da-peng. Clinical effect of maintenance chemotherapy with Gemcitabine in the treatment of advanced lung squamous cell carcinoma[J]. 中国当代医药, 2021, 28(12): 112-114转118.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I12/112

[1]	刘厚强，崔艳.吉西他滨联合替吉奥二线治疗老年ⅢB 期肺鳞癌的疗效及安全性探讨[J].中外医疗，2017，36（1）：122-124.
[2]	陈泽勉.晚期肺鳞癌采取奈达铂与顺铂结合吉西他滨化疗的效果对比分析[J].北方药学，2019，16（7）：15-16.
[3]	支修益，刘德若，陈东红，等.原发性肺癌诊疗规范（2011年版）[J].中国肺癌杂志，2012，15（12）：677-688.
[4]	付晖.铂类药物联合吉西他滨、多西他赛治疗晚期肺鳞癌的效果观察[J].临床医学，2019，39（2）：98-100.
[5]	安勇鹏.吉西他滨同药维持化疗治疗晚期肺鳞癌的临床研究[J].中国医学工程，2018，26（12）：10-13.
[6]	赵敏.吉西他滨联合顺铂与多西他赛联合顺铂治疗晚期肺鳞癌临床效果对比分析[J].医药前沿，2019，9（36）：79-80.
[7]	谢猛，王娟娟，李明.血管内皮抑素联合吉西他滨和顺铂治疗老年晚期肺鳞癌的效果及对外周血相关肿瘤因子水平的影响[J].中国老年学杂志，2020，40（7）：1425-1427.
[8]	王伟，孔天东，沈志博.洛铂联合吉西他滨治疗晚期肺鳞癌疗效分析[J].肿瘤基础与临床，2016，29（1）：26-29.
[9]	张洪琼.吉西他滨联合顺铂方案与多西他赛联合奈达铂方案对晚期肺鳞癌的疗效比较[J].实用癌症杂志，2017，32（7）：1156-1158.
[10]	苟佳丽.吉西他滨联合顺铂方案与多西他赛联合奈达铂方案治疗晚期肺鳞癌的对比观察[J].临床合理用药杂志，2017，10（22）：25-27.
[11]	刘雨晴，贾建伟，姚毅波.吉西他滨联合顺铂治疗晚期肺鳞癌的临床疗效和安全性分析[J].航空航天医学杂志，2017，28（6）：724-726.
[12]	李均勇.联用吉西他滨与洛铂对晚期肺鳞癌患者进行治疗的效果探析[J].当代医药论丛，2017，15（5）：29-30.
[13]	安改丽，陈小龙，郭维，等.吉西他滨联合顺铂治疗晚期肺鳞癌的疗效及生存情况分析[J].癌症进展，2017，15（12）：1433-1435.
[14]	宋文灿，鲍瑜，钱江，等.恩度联合吉西他滨和顺铂治疗晚期肺鳞癌的临床疗效及对患者生活质量的影响[J].实用癌症杂志，2018，33（1）：59-62.
[15]	陈德和.吉西他滨联合奈达铂与吉西他滨联合卡铂对老年晚期肺鳞癌的疗效观察[J].海军医学杂志，2018，39（3）：280-282.